CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis
USA - NASDAQ:CORT - US2183521028 - Common Stock
72.87 USD
-1.46 (-1.96%)
72 USD
-0.87 (-1.19%)
CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. CORT gets an excellent profitability rating and is at the same time showing great financial health properties. CORT is growing strongly while it is still valued neutral. This is a good combination! These ratings would make CORT suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CORT was profitable.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
Each year in the past 5 years CORT had a positive operating cash flow.
1.2 Ratios
CORT has a better Return On Assets (16.67%) than 95.90% of its industry peers.
CORT has a Return On Equity of 21.02%. This is amongst the best in the industry. CORT outperforms 92.31% of its industry peers.
CORT has a better Return On Invested Capital (13.39%) than 91.28% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CORT is above the industry average of 15.28%.
The last Return On Invested Capital (13.39%) for CORT is well below the 3 year average (17.94%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.67% | ||
| ROE | 21.02% | ||
| ROIC | 13.39% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
Looking at the Profit Margin, with a value of 18.66%, CORT belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
CORT's Profit Margin has declined in the last couple of years.
CORT's Operating Margin of 14.24% is amongst the best of the industry. CORT outperforms 85.13% of its industry peers.
In the last couple of years the Operating Margin of CORT has declined.
CORT's Gross Margin of 98.37% is amongst the best of the industry. CORT outperforms 98.46% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.24% | ||
| PM (TTM) | 18.66% | ||
| GM | 98.37% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CORT has been increased compared to 1 year ago.
The number of shares outstanding for CORT has been reduced compared to 5 years ago.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 31.13 indicates that CORT is not in any danger for bankruptcy at the moment.
CORT's Altman-Z score of 31.13 is amongst the best of the industry. CORT outperforms 96.41% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 31.13 |
ROIC/WACC1.36
WACC9.88%
2.3 Liquidity
CORT has a Current Ratio of 3.06. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT's Current ratio of 3.06 is in line compared to the rest of the industry. CORT outperforms 56.92% of its industry peers.
A Quick Ratio of 2.98 indicates that CORT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.98, CORT is in line with its industry, outperforming 57.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.06 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
The earnings per share for CORT have decreased by 0.00% in the last year.
The Earnings Per Share has been growing by 9.71% on average over the past years. This is quite good.
Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 25.71%.
The Revenue has been growing by 17.11% on average over the past years. This is quite good.
EPS 1Y (TTM)0%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-9.38%
Revenue 1Y (TTM)25.71%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%18.7%
3.2 Future
CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.78% yearly.
The Revenue is expected to grow by 30.85% on average over the next years. This is a very strong growth
EPS Next Y-1.91%
EPS Next 2Y40.87%
EPS Next 3Y66.42%
EPS Next 5Y54.78%
Revenue Next Year24.8%
Revenue Next 2Y31.08%
Revenue Next 3Y31.29%
Revenue Next 5Y30.85%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CORT is valuated quite expensively with a Price/Earnings ratio of 64.49.
77.44% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.30. CORT is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 29.61 indicates a quite expensive valuation of CORT.
Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than the industry average as 71.28% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, CORT is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.49 | ||
| Fwd PE | 29.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 76.92% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 78.46% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.59 | ||
| EV/EBITDA | 69.77 |
4.3 Compensation for Growth
The excellent profitability rating of CORT may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 66.42% in the coming years.
PEG (NY)N/A
PEG (5Y)6.64
EPS Next 2Y40.87%
EPS Next 3Y66.42%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
72.87
-1.46 (-1.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.63%
Inst Owner Change-4.95%
Ins Owners6.55%
Ins Owner Change-0.03%
Market Cap7.68B
Analysts82
Price Target137.19 (88.27%)
Short Float %11.37%
Short Ratio9.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.3%
Min EPS beat(2)16.96%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)17.73%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)18.86%
EPS beat(12)9
Avg EPS beat(12)14.75%
EPS beat(16)12
Avg EPS beat(16)12.32%
Revenue beat(2)0
Avg Revenue beat(2)-8.89%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-4.4%
Revenue beat(4)1
Avg Revenue beat(4)-5.99%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)5
Avg Revenue beat(8)-1.83%
Revenue beat(12)6
Avg Revenue beat(12)-1.82%
Revenue beat(16)7
Avg Revenue beat(16)-2.2%
PT rev (1m)0%
PT rev (3m)-3.58%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-67.16%
EPS NY rev (1m)-13.43%
EPS NY rev (3m)-13.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.53%
Revenue NY rev (1m)-3.85%
Revenue NY rev (3m)-3.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.49 | ||
| Fwd PE | 29.61 | ||
| P/S | 10.72 | ||
| P/FCF | 42.59 | ||
| P/OCF | 42.14 | ||
| P/B | 12.08 | ||
| P/tB | 12.08 | ||
| EV/EBITDA | 69.77 |
EPS(TTM)1.13
EY1.55%
EPS(NY)2.46
Fwd EY3.38%
FCF(TTM)1.71
FCFY2.35%
OCF(TTM)1.73
OCFY2.37%
SpS6.8
BVpS6.03
TBVpS6.03
PEG (NY)N/A
PEG (5Y)6.64
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.67% | ||
| ROE | 21.02% | ||
| ROCE | 15.52% | ||
| ROIC | 13.39% | ||
| ROICexc | 28.18% | ||
| ROICexgc | 28.18% | ||
| OM | 14.24% | ||
| PM (TTM) | 18.66% | ||
| GM | 98.37% | ||
| FCFM | 25.18% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 101.43% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 175.46% | ||
| Profit Quality | 134.88% | ||
| Current Ratio | 3.06 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z | 31.13 |
F-Score6
WACC9.88%
ROIC/WACC1.36
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-9.38%
EPS Next Y-1.91%
EPS Next 2Y40.87%
EPS Next 3Y66.42%
EPS Next 5Y54.78%
Revenue 1Y (TTM)25.71%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%18.7%
Revenue Next Year24.8%
Revenue Next 2Y31.08%
Revenue Next 3Y31.29%
Revenue Next 5Y30.85%
EBIT growth 1Y-20.33%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-34.64%
EBIT Next 3Y41.42%
EBIT Next 5Y19.15%
FCF growth 1Y33.84%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y34.76%
OCF growth 3Y5.66%
OCF growth 5Y7.79%